Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 3/20 | 0.45 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614118 | 0.85 | KRAS (0.40) | TSPOKRASLMNAALDH1A1KDM4E | |
| SCHEMBL4259833 | 0.82 | LMNA (0.48) | TSPOKRASLMNAALDH1A1PTGDR2 | |
| SCHEMBL5871651 | 0.81 | P2RX4 (0.51) | TSPOLMNAALDH1A1KDM4EP2RX4 | |
| SCHEMBL22122219 | 0.79 | KRAS (0.43) | KRASALDH1A1KDM4EERN1CYP2A6 | |
| SCHEMBL3410215 | 0.78 | TSPO (0.42) | TSPOKRASLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL7715925 | 0.74 | HTR6 (0.44) | KRASL3MBTL1ALDH1A1KDM4EERN1 | |
| SCHEMBL22122327 | 0.74 | GAA (0.52) | KRASLMNAALDH1A1KDM4EERN1 | |
| SCHEMBL5437254 | 0.71 | ALDH1A1 (0.66) | KRASALDH1A1KDM4EERN1CYP2A6 | |
| SCHEMBL671605 | 0.71 | PDE4B (0.46) | KRASLMNAALDH1A1KDM4EERN1 | |
| SCHEMBL22798889 | 0.70 | ALDH1A1 (0.70) | KRASLMNAL3MBTL1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816328-B2 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100004160-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | RYBCZYNSKI PHILIP | 2010-01-07 | — | — | US | disclosed |
| EP-1679965-A4 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | disclosed |
| US-20090105162-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | RYBCZYNSKI PHILIP | 2009-04-23 | — | — | US | disclosed |
| US-7482330-B2 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-27 | — | — | US | disclosed |
| US-20060229260-A1 | Substituted fused heterocyclic C-glycosides | Tanabe Pharma Corporation (JP) | 2006-10-12 | — | — | US | disclosed |
| US-7094763-B2 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARACEUTICA, N.V. (BE) | 2006-08-22 | — | — | US | disclosed |
| EP-1679965-A2 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-19 | — | — | EP | disclosed |
| US-20050037980-A1 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
| WO-2005012318-A2 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004160-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | UGCG, UGGT1, GCG | TSPO 3433/4885KRAS 2239/4885LMNA 309/4885 |
| US-20060229260-A1 | Substituted fused heterocyclic C-glycosides | UGCG, UGGT1, GCG | TSPO 3433/4885KRAS 2239/4885LMNA 309/4885 |
| US-20090105162-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | UGCG, UGGT1, GCG | TSPO 3433/4885KRAS 2239/4885LMNA 309/4885 |
| US-20050037980-A1 | Substituted fused heterocyclic C-glycosides | UGCG, UGGT1, GCG | TSPO 3433/4885KRAS 2239/4885LMNA 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.